Antidepressants as a treatment for hot flashes in women

American Journal of Health-System Pharmacy

Volumn 61, Issue 3, 2004, Pages 287-292

  Kockler, Denise R ^a   McCarthy, Michelle W ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ALPHA TOCOPHEROL; ANASTROZOLE; ANTIDEPRESSANT AGENT; BELLADONNA ALKALOID; CLONIDINE; DOPAMINE; ESTROGEN; FLUOXETINE; GABAPENTIN; HORMONE; METHYLDOPA; NORADRENALIN; PAROXETINE; PROPRANOLOL; SEROTONIN; TAMOXIFEN; VENLAFAXINE;

ANXIETY DISORDER; APPETITE DISORDER; BREAST CANCER; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEMALE; HEADACHE; HEART DISEASE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INSOMNIA; MENOPAUSE; META ANALYSIS; MOOD DISORDER; NERVOUSNESS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEROTONIN BLOOD LEVEL; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREMOR; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; FEMALE; HOT FLASHES; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 2942536031     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.3.287     Document Type: Review

References (35)

1. Carr BR. Disorders of the ovaries and female reproductive tract. In: Wilson JD, Foster DW, Kronenberg HM et al., eds. Williams textbook of endocrinology. 9th ed. Philadelphia: W.B. Saunders; 1998: 777,804.
2. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999; 353:571-80.
3. Overlie I, Moen MH, Holte A et al. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas. 2002; 41:69-77.
4. Lobo RA, McCormick W, Singer F et al. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol. 1984; 63:1-5.
5. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril. 1998; 70:332-7.
6. Loprinzi CL, Pisanski TM, Fonseca R et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998; 16:2377-81.
7. Notelovitz M, Lenihan JP, McDermott M et al. Initial 17 beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000; 95:726-31.
8. Nand SL, Webster MA, Baber R et al. Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Climacteric. 1998; 1:211-8.
9. Greendale GA, Reboussin BA, Hogan P et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998; 92:982-8.
10. Young RL, Kumar NS, Goldzieher JW. Management of menopause when estrogen cannot be used. Drugs. 1990; 40:220-30.
11. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: executive summary and consensus statement. Oncology. 1999; 56:859-75.
12. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321-33.
13. Goldberg RM, Loprinzi CL, O'Fallon JR et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994; 12:155-8.
14. Pandya KJ, Raubertas RF, Flynn PJ et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000; 132:788-93.
15. Nesheim BI, Saetre T. Reduction of hot flashes by methyldopa: a double blind crossover trial. Eur J Clin Pharmacol. 1981; 20:413-6.
16. Hammond MG, Hatley L, Talbert LM. A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab. 1984; 58:1158-60.
17. Coope J, Williams S, Patterson JS. A study of the effectiveness of propranolol in menopausal hot flushes. Br J Obstet Gynaecol. 1978; 85:472-5.
18. Barton DL, Loprinzi CL, Quella SK et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998; 16:495-500.
19. Bergmans MG, Merkus JM, Corbey RS et al. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas. 1987; 9:227-34.
20. Guttuso T Jr, Kurlan R, McDermontt MP et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003; 101:337-45.
21. Albertazzi P, Bottazzi M, Purdie DW. Gabapentin for the management of hot flushes: a case series. Menopause. 2003; 10:214-7.
22. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002; 137:805-13.
23. U.S. Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. Public law 103-417. www. fda.gov/opacom/laws/dshea.html (accessed 2003 Jul 22).
24. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000; 356:2059-63.
25. Barton D, LaVasseur B, Loprinzi C et al. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum. 2002; 29:33-40.
26. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002; 20:1578-83.
27. Weitzner MA, Moncello J, Jacobsen PB et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage. 2002; 23:337-45.
28. Stearns V, Isaacs C, Rowland J et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000; 11:17-22.
29. Stearns V, Beebe KL, Iyengar M et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003; 289:2827-34.
30. Gonzales GF, Carrillo C. Blood serotonin levels in postmenopausal women: effects of age and serum oestradiol levels. Maturitas. 1993; 17:23-9.
31. Stearns V, Ullmer L, Lopez JF et al. Hot flushes. Lancet. 2002; 360:1851-61.
32. Gudelsky GA, Koenig JI, Meltzer HY. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology. 1986; 25:1307-13.
33. Berendsen HH, Broekkamp CL. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol. 1990; 101:667-73.
34. Sloan JA, Loprinzi CL, Novotny PJ et al. Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001; 19:4280-90.
35. Nolvadex package insert. Wilmington, DE: AstraZeneca Pharmaceuticals; 2002 May.